E85.82 Wild-type transthyretin-related (ATTR) amyloidosis

Name of the Condition

• Wild-type transthyretin-related (ATTR) amyloidosis
• ICD-10 Code: E85.82

Summary

Wild-type transthyretin-related (ATTR) amyloidosis is a disorder characterized by the abnormal deposition of transthyretin protein in tissues and organs, disrupting normal function. This buildup can affect multiple body systems, including the heart, nerves, and other organs, leading to a range of clinical manifestations.

Causes

The condition is caused by the misfolding and aggregation of wild-type transthyretin protein, which deposits as amyloid fibrils in organs. Unlike hereditary forms, wild-type ATTR amyloidosis is not associated with genetic mutations in the transthyretin gene. The exact trigger for protein misfolding remains unclear, but age-related changes in protein stability are thought to play a role.

Risk Factors

• Advanced age (more common in older adults).
• Male gender (higher prevalence in men).
• Family history of amyloidosis (in some cases, though not genetically inherited).
• Prior cardiac or neurological conditions (may increase susceptibility).

Symptoms

• Fatigue and unexplained weight loss.
• Swelling in the ankles, legs, or abdomen (edema).
• Shortness of breath or heart palpitations (cardiac involvement).
• Numbness or tingling in the hands or feet (peripheral neuropathy).
• Gastrointestinal symptoms like diarrhea or constipation.
• Carpal tunnel syndrome (often an early sign).
• Liver enlargement or abnormal liver function tests.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and tissue biopsy. Biopsy samples are stained with Congo red to confirm amyloid deposits. Additional tests may include imaging studies (e.g., echocardiogram, MRI) to assess organ involvement and specialized blood or urine tests to detect amyloid proteins. Genetic testing is not typically required for wild-type ATTR, as it is not hereditary.

Treatment Options

Treatment focuses on managing symptoms and slowing disease progression. Options may include medications to stabilize transthyretin, manage heart failure, or relieve neuropathic pain. In some cases, organ transplantation (e.g., heart or liver) may be considered. Supportive care, such as physical therapy or dietary modifications, is also important.

Prognosis and Follow-Up

Prognosis varies depending on the organs involved and the severity of symptoms. Early diagnosis and treatment can improve outcomes, but the condition is often progressive. Regular follow-up with specialists (e.g., cardiologists, neurologists) is recommended to monitor organ function and adjust treatment as needed.

Complications

• Progressive heart failure or arrhythmias.
• Severe peripheral neuropathy affecting mobility.
• Kidney dysfunction or failure.
• Gastrointestinal complications (e.g., malabsorption).
• Increased risk of falls due to neuropathy.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid smoking and limit alcohol intake, as these may worsen organ function.
• Monitor for early symptoms (e.g., carpal tunnel syndrome) and seek prompt evaluation.
• Follow up with healthcare providers regularly, especially if risk factors are present.

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained swelling, shortness of breath, or numbness/tingling in the extremities. Early evaluation is important for timely diagnosis and management.

Tips for Medical Coders

Document the clinical context, including organ involvement (e.g., cardiac, neurological) and diagnostic findings (e.g., biopsy results, imaging). Ensure the code E85.82 is used when wild-type transthyretin-related amyloidosis is confirmed, and avoid coding for hereditary forms (which use different codes). Include details about symptoms, tests, and treatment to support accurate coding and billing.